# Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.

> **NCT03427866** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 44 (actual)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT03427866
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-28
- **Primary completion:** 2024-05-01
- **Final completion:** 2025-05-19
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2025-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03427866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03427866, "Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03427866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*